Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

A legfontosabb adatok

Ki végzi
Mayra Guerrero
Hol
Boston, Fort Collins, Gilbert, Los Angeles, Murray, New York, Norfolk, Phoenix, Portland, Rochester, San Antonio, San Francisco, Tucson, Tulsa és Washington D.C. (Egyesült Államok)Mind a 16 helyszín megnézéseMég 1 másik országban, 1 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
210 fő, tervezett
Kezdés
2021. márc. 8.
Várható befejezés
2030. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Transseptal ViMAC
A regiszteradat frissítve
2026. január 13.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 37 feltétel megnézéseKevesebb

Ki vehet részt

  • All Candidates must meet the following criteria:
  • - 18 years of age or older
  • -Severe mitral annular calcification with symptomatic mitral valve dysfunction including severe mitral stenosis defined as mitral valve area (MVA) of ≤1.5 cm2, or ≥ moderate to severe mitral regurgitation, or mixed ≥ moderated stenosis and ≥ moderate regurgitation. For this study, the severity of mitral regurgitation will be graded according to the 2017 American Society of Echocardiography Guidelines: None, Trivial, Mild 1(+), Moderate 2(+), Moderate to severe 3(+), and severe 4(+)
  • - NYHA Functional Class ≥II
  • The heart team agrees that valve implantation will likely benefit the patient
  • High or prohibitive risk for standard mitral valve surgery as determined by the heart team (at least one site cardiac surgeon must personally examine the subject to determine operative risk in patients presented for inclusion to ViMAC arm). NOTE: Patients not interested in mitral intervention or who are being considered for inclusion in the Natural History of Disease Registry are not required to be evaluated in person by a surgeon.)
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site
  • The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years

Ki nem vehet részt

  • Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not exclusionary
  • Severe symptomatic tricuspid regurgitation (hepatic dysfunction, ascites, edema not controlled with diuretics) requiring surgery
  • Need for emergency surgery for any reason
  • Active upper GI bleeding within 90 days prior to procedure
  • - Participating in another investigational device study
  • - The heart team considers the patient is a surgical candidate
  • - Myocardial infarction requiring revascularization within 30 days from procedure
  • - Clinically significant untreated coronary artery disease requiring revascularization
  • Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation
  • A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure
  • Cardiac anatomy that would preclude appropriate delivery and deployment of an Edwards SAPIEN 3/Ultra/RESILIA valve in MAC via transseptal access, including but not limited to:; Native neo mitral annulus size < 275 mm2 or > 810 mm2 as measured by CT scan; Significant risk of LVOT obstruction or valve embolization as assessed by CT core lab
  • Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 90 days of the procedure
  • Estimated life expectancy <12 months due to non-cardiac conditions
  • - Active infection requiring antibiotic therapy (subject may be a candidate after 2 weeks of antibiotic discontinuation
  • - Aortic valve disease requiring intervention. If aortic valve intervention is required, the AVR procedure should be performed first and if the patient remains symptomatic after AVR, may be presented for consideration for inclusion in this trial
  • - Severe fixed pulmonary hypertension (PASP ≥70 mmHg and more than 2/3 of the systemic systolic blood pressure)
  • - Severe chronic obstructive pulmonary disease requiring continuous home oxygen
  • - Recent symptomatic COVID-19 infection with residual symptoms that may affect the outcomes of this trial
  • Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), Thrombocytopenia (Platelets < 50,000 cell/mL), history of coagulopathy or hypercoagulable state
  • Severe left ventricular dysfunction with LVEF < 20%
  • - Mitral annulus is not severely calcified
  • Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to ViMAC procedure after a qualifying Echo)
  • Hypertrophic obstructive cardiomyopathy (HOCM) with mean LVOT gradient of ≥20 mm Hg at rest or ≥50 mmHg with Valsalva
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • Expectation that patient will not improve despite treatment of mitral valve dysfunction
  • Active bacterial endocarditis within 180 days of procedure
  • - Severe right ventricular dysfunction as assessed by Echo core lab
  • - Female who is pregnant or lactating
  • - The patient refuses mitral valve intervention

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

Még 1 másik országban, 1 helyszínen

  • Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: Sinead CoyleRésztvevőt keres
  • Massachusetts General HospitalBoston, Egyesült ÁllamokContact: Lina FuRésztvevőt keres
  • Uchealth Heart & Vascular Clinic Harmony CampusFort Collins, Egyesült ÁllamokContact: Tatiana Kaptzan, Ph. D.No longer taking part
  • Dignity Health Chandler Regional Medical CenterGilbert, Egyesült ÁllamokContact: Jennifer VermillionRésztvevőt keres
  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Khaled AlsabaawiRésztvevőt keres
  • Intermountain Medical CenterMurray, Egyesült ÁllamokContact: Brenda CarrollRésztvevőt keres
  • Columbia University Medical Center/NYPHNew York, Egyesült ÁllamokContact: Kate DaltonRésztvevőt keres
  • The Sentara Heart Valve and Structural Disease CenterNorfolk, Egyesült ÁllamokContact: Tatiana Kaptzan, Ph. D.No longer taking part
  • Banner - University Medicine Cardiology ClinicPhoenix, Egyesült ÁllamokContact: Yi DaiRésztvevőt keres
  • Oregon Health Science UniversityPortland, Egyesült ÁllamokContact: Zachary TaylorRésztvevőt keres
  • Mayo ClinicRochester, Egyesült ÁllamokContact: Tatiana Kaptzan, Ph. D.No longer taking part
  • University HealthSan Antonio, Egyesült ÁllamokContact: Rachel SteinerRésztvevőt keres
  • Sutter HealthSan Francisco, Egyesült ÁllamokContact: Milena FerreiraRésztvevőt keres
  • Pima Heart & VascularTucson, Egyesült ÁllamokContact: Adriana Olivares, MDRésztvevőt keres
  • Oklahoma Heart Institute Utica OfficeTulsa, Egyesült ÁllamokContact: Ashlee RitterRésztvevőt keres
  • MedStar Washington Hospital CenterWashington D.C., Egyesült ÁllamokContact: Eric CollinsRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.

A vizsgálat 2 csoportja

  • Transseptal ViMACA vizsgált kezelés

    110 MAC patients treated with transseptal Valve-in-MAC.

  • Registry of untreated patientsNincs vizsgálati kezelés, összehasonlításként

    100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
The Safety and Effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA (SAPIEN 3/Ultra/RESILIA) Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery.
A regiszteradat frissítve
2026. január 13.